Edward Tsai, DO
Family Medicine · Las Vegas, NVNPI 1124095195
Payments from drug & device makers
Across 384 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$824
- AbbVie$548
- Amarin Pharma, Inc.$434
- Almatica Pharma LLC$390
- Bayer$308
- plus $3K from 24 others
What the payments were for
- Food & beverage$6,94698%
- Education$1572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 107 | $1,909 |
| Novo Nordisk | 42 | $824 |
| AbbVie(2 entities) | 35 | $548 |
| Amarin Pharma, Inc. | 35 | $434 |
| Almatica Pharma LLC | 18 | $390 |
| Bayer | 15 | $308 |
| Amgen | 13 | $289 |
| Pfizer | 11 | $220 |
| Boehringer Ingelheim | 12 | $199 |
| Idorsia Pharmaceuticals US Inc | 9 | $198 |
| Inspire Medical Systems, Inc. | 1 | $196 |
| Eisai Inc. | 10 | $194 |
| Mylan Specialty L.p. | 6 | $182 |
| Lilly USA, LLC | 9 | $141 |
| Kowa Pharmaceuticals America, Inc. | 8 | $138 |
| Orexo US, Inc. | 8 | $132 |
| Johnson & Johnson | 8 | $122 |
| GSK | 5 | $117 |
| Abbott | 5 | $105 |
| Merck | 5 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $83 |
| Exact Sciences | 3 | $57 |
| Intra-sana Laboratories | 3 | $53 |
| Biohaven Pharmaceuticals, Inc. | 3 | $47 |
| Verona Pharma, Inc. | 1 | $31 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,102 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $95,990 |
| JanuviaSitagliptin Phosphate | 44 | $51,763 |
| JardianceEmpagliflozin | 52 | $50,654 |
| FarxigaDapagliflozin Propanediol | 44 | $44,128 |
| MounjaroTirzepatide | 13 | $15,011 |
| EliquisApixaban | 26 | $14,279 |
| NexletolBempedoic Acid | 12 | $13,802 |
| VascepaIcosapent Ethyl | 19 | $11,441 |
| QuviviqDaridorexant Hcl | 13 | $6,255 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,073 |
| Tenofovir Disoproxil Fumarate | 12 | $5,989 |
| Rosuvastatin Calcium | 226 | $4,392 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,001 |
| Losartan Potassium | 310 | $2,083 |
| Metoprolol Succinate | 127 | $1,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $824 | $95,99061 claims |
| MerckJanuvia | $84 | $51,76344 claims |
| Boehringer IngelheimJardiance | $199 | $50,65452 claims |
| AstraZenecaFarxiga | $1,909 | $44,12844 claims |
| Lilly USA, LLCMounjaro | $141 | $15,01113 claims |
| PfizerEliquis | $220 | $14,27926 claims |
| Esperion Therapeutics, Inc.Nexletol | $15 | $13,80212 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $198 | $6,25513 claims |
| GSKAnoro Ellipta | $117 | $6,07313 claims |
| AbbVieSynthroid | $548 | $1,10911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Rogelio MachucaLas Vegas$3.3M
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
- Robert KaplanLas Vegas$1.7M
- Sean SuLas Vegas$1.1M
- Naz WahabLas Vegas$735K
- Carmelo RilleraLas Vegas$531K
- Peter PhilanderLas Vegas$524K
- Jerry CadeLas Vegas$381K
- Dana ForteLas Vegas$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.